THE 2-MINUTE RULE FOR AGO TUMOR

Hormonal therapy continues to be the treatment method of initial option for metastatic clients with endocrine-responsive breast cancer (LoE 1a A, Back ++). The sequential use on the offered medicines depends on the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at some time of prognosis of relapse is usually recommended E